Polaris Partners — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device.
BiotechDigital HealthMental HealthCambridge, US
William Huyett(Executive Officer)Mark G. Currie(Executive Officer)Ole Isacson(Director)Stephanie Lovell(Director)Marsha Fanucci(Director)George Conrades(Director)
Board seatAmy SchulmanTerrance McGuire· per SEC Form D · $24.3M raise · filed Aug 2020
Co-investorsPappas Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.